Pertuzumab biosimilar; a humanized anti-HER2 monoclonal antibody that binds HER2 subdomain II to block ligand-dependent HER2 dimerization (especially HER2/HER3), suppress downstream PI3K/AKT and MAPK signaling, and promote ADCC.
Pertuzumab biosimilar; a humanized anti-HER2 monoclonal antibody that binds HER2 subdomain II to block ligand‑dependent HER2 dimerization (especially HER2/HER3), thereby suppressing downstream PI3K/AKT and MAPK signaling and eliciting antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
Anti-HER2 IgG1 binds HER2 and its Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells) to trigger antibody-dependent cellular cytotoxicity (ADCC), with possible complement activation; signaling blockade itself is non-cytolytic.
Humanized anti-HER2 monoclonal antibody that binds HER2 subdomain II, inhibits ligand-dependent HER2 dimerization (notably HER2/HER3), downregulates downstream PI3K/AKT and MAPK signaling, and mediates ADCC.
Humanized monoclonal antibody against HER2 (ERBB2) subdomain II that blocks ligand-dependent HER2 dimerization—particularly HER2/HER3—thereby inhibiting downstream PI3K/AKT and MAPK signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
Fc-mediated ADCC by NK cells and other effector cells against HER2-expressing cells; additionally, HER2 dimerization blockade can induce growth inhibition and apoptosis.
Humanized anti-HER2 monoclonal antibody that binds HER2 subdomain IV, inhibits ligand-independent signaling, promotes HER2 downregulation, and mediates ADCC.
Humanized anti-HER2 monoclonal antibody that binds HER2 extracellular domain IV (ERBB2), inhibits ligand-independent HER2 signaling, promotes receptor internalization/downregulation, suppresses downstream PI3K/AKT and MAPK pathways, and engages Fc receptors to mediate ADCC against HER2-overexpressing tumor cells.
YES
DIRECT
Trastuzumab binds HER2 and its Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC (±ADCP/CDC), killing HER2-expressing cells; signaling blockade may also promote apoptosis.
Type II anti-CD20 monoclonal antibody; used for B-cell debulking and to mitigate cytokine release syndrome risk.
Glycoengineered humanized IgG1 type II anti-CD20 monoclonal antibody that binds CD20 on B cells, enhancing FcγRIIIa engagement to drive strong ADCC/ADCP and inducing direct, caspase-independent apoptosis, resulting in rapid B‑cell depletion (with relatively low CDC). Used clinically for B‑cell debulking and to mitigate CRS risk with CD20×CD3 bispecifics.
YES
DIRECT
Obinutuzumab binds CD20 on B cells, engaging FcγRIIIa on NK cells/macrophages to drive ADCC/ADCP and also triggers direct, caspase‑independent apoptosis (with relatively low CDC).
Humanized anti-HER2 monoclonal antibody that binds HER2 subdomain IV, inhibits ligand-independent signaling, promotes HER2 downregulation, and mediates ADCC.
Humanized anti-HER2 monoclonal antibody that binds HER2 extracellular domain IV (ERBB2), inhibits ligand-independent HER2 signaling, promotes receptor internalization/downregulation, suppresses downstream PI3K/AKT and MAPK pathways, and engages Fc receptors to mediate ADCC against HER2-overexpressing tumor cells.
NO
INDIRECT
Trastuzumab binds HER2 on tumor cells; its Fc engages CD16a on NK cells to trigger ADCC that kills HER2-overexpressing cells, not the CD16a-expressing effector cells.